NAGE vs PATH · P/E 59, rev $99.6M vs P/E 19, rev $1.61B
Niagen Bioscience, Inc. (NAGE) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Niagen Bioscience, Inc. (NAGE) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported NAGE revenue for 2024-12-31 was $99.6M. Net income was $8.6M. Revenue was up 19.2% from 2023-12-31 to 2024-12-31. NAGE currently screens at market cap $836.5M and trailing P/E 59.0.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
NAGE currently screens at market cap $836.5M and trailing P/E 59.0. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the NAGE and PATH stock pages for the full models.
Not investment advice.